Mishka Exim Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 7:51 pm

Quick Insight

Mishka Exim Ltd, operating in the Gems, Jewellery & Precious Metals sector, currently trades at a price of ₹38.0 with a market capitalization of ₹54.9 Cr. Despite a high P/E ratio of 114, the company's Return on Equity (ROE) stands at 1.51% and Return on Capital Employed (ROCE) at 2.16%. With a low Operating Profit Margin (OPM) of 8.61% and a Net Profit of 0.33, Mishka Exim Ltd's financial health is a concern, further highlighted by a high Cash Conversion Cycle (CCC) of 490.35 days. The company's strong ICR of 21.64x provides some cushion, but the low ROE and ROCE indicate inefficiencies in capital utilization and profitability, suggesting a cautious approach for investors considering this stock.

Competitors of Mishka Exim Ltd

All Competitor Stocks of Mishka Exim Ltd

Quarterly Result

Last Updated: July 18, 2025, 12:03 pm

Below is a detailed analysis of the quarterly data for Mishka Exim Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2.09 Cr.. The value appears strong and on an upward trend. It has increased from 1.49 Cr. (Mar 2025) to 2.09 Cr., marking an increase of 0.60 Cr..
• For Expenses, as of Jun 2025, the value is 1.91 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.35 Cr. (Mar 2025) to 1.91 Cr., marking an increase of 0.56 Cr..
• For Operating Profit, as of Jun 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.04 Cr..
• For OPM %, as of Jun 2025, the value is 8.61%. The value appears to be declining and may need further review. It has decreased from 9.40% (Mar 2025) to 8.61%, marking a decrease of 0.79%.
• For Other Income, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.03 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
• For Depreciation, as of Jun 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.03 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.24 Cr.. The value appears strong and on an upward trend. It has increased from 0.17 Cr. (Mar 2025) to 0.24 Cr., marking an increase of 0.07 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.41% (Mar 2025) to 25.00%, marking a decrease of 4.41%.
• For Net Profit, as of Jun 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.12 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.06 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from 0.08 (Mar 2025) to 0.12, marking an increase of 0.04.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 23, 2025, 10:47 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 12:59 pm

Below is a detailed analysis of the balance sheet data for Mishka Exim Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.45 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.45 Cr..
• For Reserves, as of Mar 2025, the value is 7.59 Cr.. The value appears strong and on an upward trend. It has increased from 7.17 Cr. (Mar 2024) to 7.59 Cr., marking an increase of 0.42 Cr..
• For Borrowings, as of Mar 2025, the value is 0.27 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.03 Cr. (Mar 2024) to 0.27 Cr., marking an increase of 0.24 Cr..
• For Other Liabilities, as of Mar 2025, the value is 3.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.12 Cr. (Mar 2024) to 3.59 Cr., marking an increase of 1.47 Cr..
• For Total Liabilities, as of Mar 2025, the value is 25.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.77 Cr. (Mar 2024) to 25.90 Cr., marking an increase of 2.13 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2.10 Cr.. The value appears to be declining and may need further review. It has decreased from 2.23 Cr. (Mar 2024) to 2.10 Cr., marking a decrease of 0.13 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 16.76 Cr.. The value appears strong and on an upward trend. It has increased from 16.65 Cr. (Mar 2024) to 16.76 Cr., marking an increase of 0.11 Cr..
• For Other Assets, as of Mar 2025, the value is 7.04 Cr.. The value appears strong and on an upward trend. It has increased from 4.89 Cr. (Mar 2024) to 7.04 Cr., marking an increase of 2.15 Cr..
• For Total Assets, as of Mar 2025, the value is 25.90 Cr.. The value appears strong and on an upward trend. It has increased from 23.77 Cr. (Mar 2024) to 25.90 Cr., marking an increase of 2.13 Cr..

Notably, the Reserves (7.59 Cr.) exceed the Borrowings (0.27 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Mishka Exim Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 5. It has increased from 0.18 (Mar 24) to 0.23, marking an increase of 0.05.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 5. It has increased from 0.18 (Mar 24) to 0.23, marking an increase of 0.05.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 3. It has increased from 0.26 (Mar 24) to 0.31, marking an increase of 0.05.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.25. It has increased from 15.14 (Mar 24) to 15.25, marking an increase of 0.11.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.25. It has increased from 15.14 (Mar 24) to 15.25, marking an increase of 0.11.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 3.23. It has increased from 2.82 (Mar 24) to 3.23, marking an increase of 0.41.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 2. It has increased from 0.38 (Mar 24) to 0.41, marking an increase of 0.03.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.32. This value is within the healthy range. It has increased from 0.28 (Mar 24) to 0.32, marking an increase of 0.04.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has increased from 0.26 (Mar 24) to 0.30, marking an increase of 0.04.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 2. It has increased from 0.16 (Mar 24) to 0.22, marking an increase of 0.06.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.23, marking an increase of 0.06.
• For PBDIT Margin (%), as of Mar 25, the value is 12.73. This value is within the healthy range. It has decreased from 13.57 (Mar 24) to 12.73, marking a decrease of 0.84.
• For PBIT Margin (%), as of Mar 25, the value is 10.15. This value is within the healthy range. It has increased from 10.10 (Mar 24) to 10.15, marking an increase of 0.05.
• For PBT Margin (%), as of Mar 25, the value is 9.56. This value is below the healthy minimum of 10. It has increased from 9.48 (Mar 24) to 9.56, marking an increase of 0.08.
• For Net Profit Margin (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has increased from 5.88 (Mar 24) to 7.07, marking an increase of 1.19.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.15. This value is below the healthy minimum of 8. It has increased from 6.17 (Mar 24) to 7.15, marking an increase of 0.98.
• For Return on Networth / Equity (%), as of Mar 25, the value is 1.51. This value is below the healthy minimum of 15. It has increased from 1.16 (Mar 24) to 1.51, marking an increase of 0.35.
• For Return on Capital Employeed (%), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 10. It has increased from 1.73 (Mar 24) to 1.95, marking an increase of 0.22.
• For Return On Assets (%), as of Mar 25, the value is 1.29. This value is below the healthy minimum of 5. It has increased from 1.05 (Mar 24) to 1.29, marking an increase of 0.24.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.18. It has increased from 0.17 (Mar 24) to 0.18, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 4.19. This value exceeds the healthy maximum of 3. It has decreased from 45.39 (Mar 24) to 4.19, marking a decrease of 41.20.
• For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 15.34 (Mar 24) to 0.65, marking a decrease of 14.69.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 21.64. This value is within the healthy range. It has increased from 21.62 (Mar 24) to 21.64, marking an increase of 0.02.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 13.01. This value is within the healthy range. It has increased from 10.37 (Mar 24) to 13.01, marking an increase of 2.64.
• For Enterprise Value (Cr.), as of Mar 25, the value is 37.04. It has decreased from 49.44 (Mar 24) to 37.04, marking a decrease of 12.40.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.93. This value exceeds the healthy maximum of 3. It has decreased from 12.14 (Mar 24) to 7.93, marking a decrease of 4.21.
• For EV / EBITDA (X), as of Mar 25, the value is 62.23. This value exceeds the healthy maximum of 15. It has decreased from 89.43 (Mar 24) to 62.23, marking a decrease of 27.20.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.83. This value exceeds the healthy maximum of 3. It has decreased from 12.10 (Mar 24) to 7.83, marking a decrease of 4.27.
• For Price / BV (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 2.28 (Mar 24) to 1.66, marking a decrease of 0.62.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.83. This value exceeds the healthy maximum of 3. It has decreased from 12.11 (Mar 24) to 7.83, marking a decrease of 4.28.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness